Bambusa Therapeutics

BBTX
15.9800.68% ( -0.110 )
Closed: Nov 16, 16:00:00 (EDT)

Profile

About

Bambusa Therapeutics
Bambusa Therapeutics
BBTX.US

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.

Profile

Company Name
Bambusa Therapeutics, Inc.
Market
NasdaqGS
Founded
Industry
--
Fiscal Year End
--

Related Securities

Industry

Management